Click here to read this study in the Lancet.
©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
The post #VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer first appeared on Physician's Weekly.